A Dual‐domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration
Open Access
- 11 February 2024
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 11 (15) , e2305316
Abstract
Chronic hepatitis B (CHB) remains a major public health concern because of the inefficiency of currently approved therapies in clearing the hepatitis B surface antigen (HBsAg). Antibody‐based regimens have demonstrated potency regarding virus neutralization and HBsAg clearance. However, high dosages or frequent dosing are required for virologic control. In this study, a dual‐domain‐engineered anti‐hepatitis B virus (HBV) therapeutic antibody 73‐DY is developed that exhibits significantly improved efficacy regarding both serum and intrahepatic viral clearance. In HBV‐tolerant mice, administration of a single dose of 73‐DY at 2 mg kg −1 is sufficient to reduce serum HBsAg by over 3 log 10 IU mL −1 and suppress HBsAg to < 100 IU mL −1 for two weeks, demonstrating a dose‐lowering advantage of at least tenfold. Furthermore, 10 mg kg −1 of 73‐DY sustainably suppressed serum viral levels to undetectable levels for ≈ 2 weeks. Molecular analyses indicate that the improved efficacy exhibited by 73‐DY is attributable to the synergy between fragment antigen binding (Fab) and fragment crystallizable (Fc) engineering, which conferred sustained viral suppression and robust viral eradication, respectively. Long‐term immunotherapy with reverse chimeric 73‐DY facilitated the restoration of anti‐HBV immune responses. This study provides a foundation for the development of next‐generation antibody‐based CHB therapies.Keywords
Funding Information
- Fundamental Research Funds for the Central Universities (20720220006)
- Youth Innovation Foundation of Xiamen (3502Z20206060)
- National Natural Science Foundation of China (81991491)
- National Natural Science Foundation of China (32070940)
- National Natural Science Foundation of China (32170943)
- National Natural Science Foundation of China (82202500)
This publication has 54 references indexed in Scilit:
- Humanized antibodies with broad-spectrum neutralization to avian influenza virus H5N1Antiviral Research, 2010
- Reduced elimination of IgG antibodies by engineering the variable regionProtein Engineering, Design and Selection, 2010
- Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis BGastroenterology, 2010
- Experimental Antibody Therapy of Liver Metastases Reveals Functional Redundancy between FcγRI and FcγRIVThe Journal of Immunology, 2008
- An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infectionProceedings of the National Academy of Sciences, 2006
- FcRn: an IgG receptor on phagocytes with a novel role in phagocytosisBlood, 2006
- Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)Journal of Biological Chemistry, 2006
- Antibodies from phage antibody librariesJournal of Immunological Methods, 2004
- Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigenGastroenterology, 2002
- Intracellular Inactivation of the Hepatitis B Virus by Cytotoxic T LymphocytesImmunity, 1996